Rocket Pharmaceuticals (RCKT) Current Assets (2014 - 2026)

Rocket Pharmaceuticals has disclosed Current Assets across 13 years of filings, most recently posting $149.8 million for Q1 2026.

• Current Assets for Q1 2026 came in at $149.8 million, down 53.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $149.8 million (down 53.83% YoY), and the FY2025 annual result was $192.7 million, down 49.04% from the prior year.
• Current Assets came in at $149.8 million for Q1 2026 at Rocket Pharmaceuticals, down from $192.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $446.9 million in Q3 2023 to a low of $149.8 million in Q1 2026.
• The 5-year median for Current Assets is $324.5 million (2025), against an average of $309.4 million.
• Across the five-year window, Current Assets soared 43.63% in 2023 and plunged 53.83% in 2026, its largest moves.
• Rocket Pharmaceuticals' Current Assets stood at $364.1 million in 2022, then advanced by 3.89% to $378.2 million in 2023, then slipped by 0.01% to $378.2 million in 2024, then slumped by 49.04% to $192.7 million in 2025, then retreated by 22.26% to $149.8 million in 2026.
• The last three Current Assets figures came in at $149.8 million (Q1 2026), $192.7 million (Q4 2025), and $227.7 million (Q3 2025), per Business Quant data.